Market Overview

JMP: MannKind Investors Need 'Clarity'

Share:

JMP’s Jason N. Butler reiterated a Market Perform rating on MannKind Corporation (NASDAQ: MNKD), while noting that “Afrezza remains in limbo as we await clarity on the commercialization plan and funding options.”

Earnings Miss

The company reported its 4Q15 earnings below the estimates and consensus, driven primarily by impairment charges associated with Afrezza.

Butler pointed out that MannKind ended 4Q15 with cash of $59 million, apart from $30 million that is under the loan arrangement with the Mann Group.

The company ended 4Q15 with $59MM in cash, not including $30MM remaining under the loan arrangement with the Mann Group.

Management Announced

MannKind has also announced the hiring of Michael Castagna as its new CCO, along with resignation of COO Juergen Martens.

“Management reiterated plans to market Afrezza itself after receiving the rights back from Sanofi SA (ADR) (NYSE: SNY) on April 5, and anticipates detailing its commercialization strategy at that time,” the JMP report said.

Insufficient Cash?

Butler also mentioned that the 2016 guidance indicates lower R&D spend, with higher selling expenses. However, if there is no improvement in Afrezza sales, and if the Mann facility is “not drawn upon”, management believes that the cash would be adequate only through 2H16.

Latest Ratings for MNKD

DateFirmActionFromTo
May 2019Initiates Coverage OnBuy
Mar 2019Initiates Coverage OnOutperform
Feb 2019Initiates Coverage OnOutperform

View More Analyst Ratings for MNKD
View the Latest Analyst Ratings

Posted-In: Jason N. Butler JMP SecuritiesAnalyst Color Biotech Reiteration Analyst Ratings General

 

Related Articles (MNKD + SNY)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
SONVertical GroupUpgrades
UNPMorgan StanleyMaintains136.0
WNSCitigroupMaintains74.0
CAKEMorgan StanleyMaintains43.0
TXRHMorgan StanleyMaintains54.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Susquehanna Downgrades Noble Corp. To Neutral Following Recent Rally

The Children's Place Q4 Earnings Conference Call: Full Transcript